Abstract | BACKGROUND AND AIM: Diabetes and its treatment can cause problems for the Muslim population. The aim of this study was to evaluate the effect of different therapy models on clinical and metabolic status in type 2 diabetic patients during Ramadan. MATERIAL AND METHODS: RESULTS: CONCLUSION: Our results conclude that Ramadan fasting affects metabolic parameters in type 2 diabetes and hypoglycemia should be kept in mind especially in patients using sulfonylurea treatment. Ramadan fasting is not advised for type 2 diabetics while taking medical therapy. If the patient wants Ramadan fasting, these patients using Repaglinide can reduce the frequency of hypoglycemia.
|
Authors | Ramazan Sari, Mustafa Kemal Balci, Sadika Halide Akbas, Berkant Avci |
Journal | Endocrine research
(Endocr Res)
Vol. 30
Issue 2
Pg. 169-77
(May 2004)
ISSN: 0743-5800 [Print] England |
PMID | 15473127
(Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article)
|
Chemical References |
- Blood Glucose
- Carbamates
- Cholesterol, HDL
- Hypoglycemic Agents
- Piperidines
- Sulfonylurea Compounds
- Triglycerides
- repaglinide
- 3-Hydroxybutyric Acid
|
Topics |
- 3-Hydroxybutyric Acid
(blood)
- Blood Glucose
(metabolism)
- Carbamates
(therapeutic use)
- Cholesterol, HDL
(blood)
- Diabetes Mellitus, Type 2
(blood, diet therapy, drug therapy)
- Fasting
(blood)
- Humans
- Hypoglycemic Agents
(therapeutic use)
- Islam
- Middle Aged
- Piperidines
(therapeutic use)
- Postprandial Period
- Sulfonylurea Compounds
(therapeutic use)
- Triglycerides
(blood)
|